Seeking Alpha

Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to...

Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|